Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine in different dose levels as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perineural Dexmedetomidine and Femoral Nerve Block

NCT01964040

Onset and Duration of Sensory and Motor Block of Femoral Nerve, Visual Analogue Pain Scores, Time to First Request of Rescue Analgesics, +1 more

UNKNOWN PHASE4

Dexamethasone Versus Demedetomidine Addition for Adductor Canal Block

NCT06527976

Postoperative Pain

COMPLETED NA

Dexmedetomidine as an Additive for (Ipack)Block in Knee Surgery

NCT07058493

Knee Surgeries

COMPLETED NA

Perineural Dexmedetomidine in Adductor Canal Block

NCT03030950

Arthroscopic Medial Meniscectomy

COMPLETED PHASE4

Comparing Dexamethasone With Dexmedetomidine as Additives to Bupivacaine in Adductor Canal Block for Knee Arthroscopy.

NCT04631822

Pain, Postoperative

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dexmedetomidine Femoral Nerve Block Arthroscopic Knee Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group B: control bupivacaine group

Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally

Group Type PLACEBO_COMPARATOR

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Intervention Type DRUG

ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.

After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Placebo

Intervention Type DRUG

Group B-DEX 25 : Peri-neural Dexmedetomidine

Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally

Group Type EXPERIMENTAL

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Intervention Type DRUG

ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.

After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Group B-DEX 50:Peri-neural Dexmedetomidine

Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally

Group Type EXPERIMENTAL

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Intervention Type DRUG

ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.

After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Group B-DEX 75:Peri-neural Dexmedetomidine

Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally

Group Type EXPERIMENTAL

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Intervention Type DRUG

ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.

After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.

After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients with ASA physical status I or II, scheduled for arthroscopic knee surgery

Exclusion Criteria

* Patients who are refusing regional block, patients with diabetic peripheral neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture site, and history of allergic reaction to study medications

Minimum Eligible Age

15 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No